Please try another search
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. The company has a collaboration with Hokkaido University and Kanazawa University to evaluate the potential of the drug candidate compounds as novel drugs, as well as a joint research agreement with Teikyo University to identify biomarkers for renal function and a strategic alliance with Ji Xing Pharmaceuticals Limited. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.
Name | Age | Since | Title |
---|---|---|---|
Kazuo Honda | - | - | Statutory Auditor |
Kenichi Nakamura | - | - | Statutory Auditor |
Hiroyuki Hasegawa | - | - | Statutory Auditor |
Takuro Wakabayashi | 57 | 2011 | President & Representative Director |
Ken Takanashi | 60 | 2020 | Independent Outside Director |
Reiko Namikawa | 71 | 2021 | Independent Outside Director |
Tsuyoshi Ito | 54 | 2018 | Director & CFO |
Noriaki Inamura | 69 | 2015 | Executive Vice President of Development & Director |
Keiji Hasumi | 67 | 2005 | Founder, Chief Scientific Officer & Chairman |
Nobuaki Kobayashi | 70 | 2021 | Chairman of Corporate Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review